Home > About GAMMAGARD LIQUID > GAMMAGARD LIQUID SubQ

GAMMAGARD LIQUID for
Subcutaneous (SubQ) Administration

Sustained Protection Against Infection1

In the SubQ administration clinical study, 49 patients with PI were given SubQ treatment with GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% Solution. Treatment efficacy was demonstrated with patients treated for a mean of 54 weeks (range 8 to 68 weeks).1

  • Low rate of acute serious bacterial infections (less than 1 infection among people taking GAMMAGARD LIQUID for a whole year)
  • 3 participants had pneumonia which was treated without hospitalization.
  • 0 participants needed to be hospitalized for an infection (or for treatment of an infection)

Demonstrated Tolerability1

In a total of 2,294 infusions in the clinical study, the most common side effect for GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% Solution was local infusion site reactions (2.4%).

The most common side effects (seen in ≥5% of patients) were local Infusion site reactions, headache, fatigue, increased heart rate, fever, upper abdominal pain, nausea, vomiting, asthma, increased blood pressure, diarrhea, ear pain, canker sores, migraine, sore throat, and pain in the hands or feet.

Please see below for additional Important Safety Information.

of infusions were completed without reducing the infusion rate or stopping the infusion due to
side effects or tolerability issues.


GAMMAGARD LIQUID treatment is formulated with1:

  • Added Sugars1
  • Added Sodium1
  • Added Preservatives1

  • Stabilized and buffered with glycine1 for those patients in whom additives may be a concern
  • The packaging is not made with natural rubber latex1

Reference: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc.


  • MyIgSource is a patient support program for all PI patients and caregivers throughout your journey. Sign up to get access to experienced Patient and Nurse Advocates, get information about insurance and financial support, useful tools, and more.
    Learn More
  • Ask an Advocate Questions about PI or PI treatments? Our trained Patient and Nurse Advocates can help, and asking your question is easy with our Ask An Advocate feature.
    Start Getting Answers

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.

-----

Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.


© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17

Please expand for Indication and Important Safety Information.

IMPORTANT SAFETY INFORMATION

What is the most important information that I should know about GAMMAGARD LIQUID?

GAMMAGARD LIQUID can cause the following serious reactions: severe allergic reactions causing difficulty in breathing or skin rashes; decreased kidney function or kidney failure; blood clots in the heart, brain, lungs or elsewhere in the body; severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting; dark colored urine, swelling, fatigue, or difficulty breathing.